A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Exclusion Criteria

• •1. Known homozygous familial hypercholesterolemia.
• •2. Received PCSK9 inhibitors within 6 months before randomization.
• •3. Known sensitivity to PCSK9 inhibitors and any substances to be administered.
• •4. Severe renal dysfunction.
• •5. Previously received organ transplantation.
• •6. Uncontrolled hypothyroidism or hyperthyroidism.
• •7. Uncontrolled hypertension.
• •8. Known hyperlipidemia secondary to comorbidity, including nephrotic syndrome, cholestatic liver failure, etc.
• •9. History of malignancy of any organ system within the past 5 years.